|Bid||0.00 x 36200|
|Ask||0.00 x 28000|
|Day's Range||7.67 - 7.82|
|52 Week Range||5.89 - 12.20|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||5.15|
|Forward Dividend & Yield||0.31 (4.01%)|
|Ex-Dividend Date||Aug 11, 2022|
|1y Target Est||8.71|
Subscribe to Yahoo Finance Plus to view Fair Value for BCS
Chief Executive Officer C.S. Venkatakrishnan has been diagnosed with non-Hodgkin lymphoma, with treatment expected to last 12 to 16 weeks.
Barclays PLC (NYSE: BCS) CEO, C.S. Venkatakrishnan, informed the Barclays Board and his colleagues that he would be undergoing treatment for Non-Hodgkin Lymphoma. Non-Hodgkin lymphoma is a type of cancer, meaning he would work from home for some time, CNBC reports. The CEO, known inside the bank as Venkat, said in a letter that his condition was curable and that doctors have said his prognosis is “excellent,” with the treatment in New York expected to last 12 to 16 weeks. “During this period, th
Investors need to pay close attention to Barclays (BCS) stock based on the movements in the options market lately.